NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis $2.60 -0.09 (-3.16%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About InspireMD Stock (NYSE:NSPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InspireMD alerts:Sign Up Key Stats Today's Range$2.40▼$2.6050-Day Range$2.43▼$3.7052-Week Range$1.81▼$3.80Volume20,436 shsAverage Volume33,738 shsMarket Capitalization$77.34 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingBuy Company OverviewInspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Read More… Remove Ads InspireMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreNSPR MarketRank™: InspireMD scored higher than 45% of companies evaluated by MarketBeat, and ranked 626th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInspireMD has received no research coverage in the past 90 days.Read more about InspireMD's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NSPR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NSPR. News and Social Media2.0 / 5News Sentiment0.59 News SentimentInspireMD has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InspireMD this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added InspireMD to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders29.72% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InspireMD's insider trading history. Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Email Address NSPR Stock News HeadlinesInspireMD files $200M mixed securities shelfApril 2 at 9:34 PM | markets.businessinsider.comInspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | globenewswire.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Reviewing Anika Therapeutics (NASDAQ:ANIK) and InspireMD (NYSE:NSPR)March 25, 2025 | americanbankingnews.comInspireMD, Inc. (NASDAQ:NSPR) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comInspireMD, Inc. (NSPR) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | seekingalpha.comInspireMD reports Q4 EPS (19c) vs (16c) last yearMarch 12, 2025 | markets.businessinsider.comInspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue EstimatesMarch 12, 2025 | msn.comSee More Headlines NSPR Stock Analysis - Frequently Asked Questions How have NSPR shares performed this year? InspireMD's stock was trading at $2.63 on January 1st, 2025. Since then, NSPR shares have decreased by 3.1% and is now trading at $2.5490. View the best growth stocks for 2025 here. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative trailing twelve-month return on equity of 69.42% and a negative net margin of 413.96%. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/12/2024Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:NSPR CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$5.00 Low Stock Price Target$4.50 Potential Upside/Downside+86.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,920,000.00 Net Margins-413.96% Pretax Margin-413.00% Return on Equity-69.42% Return on Assets-57.68% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.05 Sales & Book Value Annual Sales$7.01 million Price / Sales10.80 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book1.39Miscellaneous Outstanding Shares29,690,000Free Float18,332,000Market Cap$75.68 million OptionableOptionable Beta0.88 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:NSPR) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.